| Reference |
|---|
Li Y, Zhou Y, Yu J, Kim Y, Li M, Lee D, et al. Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method. Nat Biotechnol. 2025;43:329-344 pubmed publisher |
Lee S, Chae S, Jang I, Oh S, Kim S, Lee S, et al. B7H6 is the predominant activating ligand driving natural killer cell-mediated killing in patients with liquid tumours: evidence from clinical, in silico, in vitro, and in vivo studies. EBioMedicine. 2024;110:105459 pubmed publisher |
Jones A, Tuy K, Hawkins C, Quinn C, Saad J, Gary S, et al. Temozolomide and the PARP Inhibitor Niraparib Enhance Expression of Natural Killer Group 2D Ligand ULBP1 and Gamma-Delta T Cell Cytotoxicity in Glioblastoma. Cancers (Basel). 2024;16: pubmed publisher |
Pascual Pasto G, McIntyre B, Hines M, Giudice A, Garcia Gerique L, Hoffmann J, et al. CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma. Nat Commun. 2024;15:7141 pubmed publisher |
Fisher J, Doyle A, Graham L, Sonar S, Sale B, Henderson I, et al. XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression. Leukemia. 2023;37:2036-2049 pubmed publisher |
Koh E, Lee H, Son W, Park G, Bae J, Park Y. Antitumor effects of NK cells expanded by activation pre‑processing of autologous feeder cells before irradiation in colorectal cancer. Oncol Lett. 2023;25:232 pubmed publisher |
de Vries N, van de Haar J, Veninga V, Chalabi M, Ijsselsteijn M, van der Ploeg M, et al. γδ T cells are effectors of immunotherapy in cancers with HLA class I defects. Nature. 2023;613:743-750 pubmed publisher |
Murayama Y, Kasahara Y, Kubo N, Shin C, Imamura M, Oike N, et al. NKp44-based chimeric antigen receptor effectively redirects primary T cells against synovial sarcoma. Transl Oncol. 2022;25:101521 pubmed publisher |
Wu H, Li K, Pan W, Guo M, Qiu D, He Y, et al. Venetoclax enhances NK cell killing sensitivity of AML cells through the NKG2D/NKG2DL activation pathway. Int Immunopharmacol. 2022;104:108497 pubmed publisher |
Fan J, Shi J, Zhang Y, Liu J, An C, Zhu H, et al. NKG2D discriminates diverse ligands through selectively mechano-regulated ligand conformational changes. EMBO J. 2022;41:e107739 pubmed publisher |
Seki T, Shimizu Y, Ishii K, Takahama Y, Kato K, Yano T. NK Cells Can Preferentially Target Prostate Cancer Stem-like Cells via the TRAIL/DR5 Signaling Pathway. Biomolecules. 2021;11: pubmed publisher |
Fu R, Yu F, Wu W, Liu J, Li J, Guo F, et al. Bufalin enhances the killing efficacy of NK cells against hepatocellular carcinoma by inhibiting MICA shedding. Int Immunopharmacol. 2021;101:108195 pubmed publisher |
Martínez Sánchez M, Fuster J, Campillo J, Galera A, Bermúdez Cortés M, Llinares M, et al. Expression of NK Cell Receptor Ligands on Leukemic Cells Is Associated with the Outcome of Childhood Acute Leukemia. Cancers (Basel). 2021;13: pubmed publisher |
Liang Y, Tsai J, Cheng Y, Chan K, Hsu W, Lee C, et al. Chemotherapy agents stimulate dendritic cells against human colon cancer cells through upregulation of the transporter associated with antigen processing. Sci Rep. 2021;11:9080 pubmed publisher |
Møller S, Mellergaard M, Madsen M, Bermejo A, Jepsen S, Hansen M, et al. Cytoplasmic Citrate Flux Modulates the Immune Stimulatory NKG2D Ligand MICA in Cancer Cells. Front Immunol. 2020;11:1968 pubmed publisher |
Høgh R, Droujinine A, Møller S, Jepsen S, Mellergaard M, Andresen L, et al. Fumarate Upregulates Surface Expression of ULBP2/ULBP5 by Scavenging Glutathione Antioxidant Capacity. J Immunol. 2020;204:1746-1759 pubmed publisher |
Suzuki D, Flahou C, Yoshikawa N, Stirblyte I, Hayashi Y, Sawaguchi A, et al. iPSC-Derived Platelets Depleted of HLA Class I Are Inert to Anti-HLA Class I and Natural Killer Cell Immunity. Stem Cell Reports. 2020;14:49-59 pubmed publisher |
Chollat Namy M, Ben Safta Saadoun T, Haferssas D, Meurice G, Chouaib S, Thiery J. The pharmalogical reactivation of p53 function improves breast tumor cell lysis by granzyme B and NK cells through induction of autophagy. Cell Death Dis. 2019;10:695 pubmed publisher |
Han Y, Xie W, Song D, Powell D. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells. J Hematol Oncol. 2018;11:92 pubmed publisher |
Kamei R, Yoshimura K, Yoshino S, Inoue M, Asao T, Fuse M, et al. Expression levels of UL16 binding protein 1 and natural killer group 2 member D affect overall survival in patients with gastric cancer following gastrectomy. Oncol Lett. 2018;15:747-754 pubmed publisher |
Pace M, Williams J, Kurioka A, Gerry A, Jakobsen B, Klenerman P, et al. Histone Deacetylase Inhibitors Enhance CD4 T Cell Susceptibility to NK Cell Killing but Reduce NK Cell Function. PLoS Pathog. 2016;12:e1005782 pubmed publisher |
Chitadze G, Lettau M, Luecke S, Wang T, Janssen O, Furst D, et al. NKG2D- and T-cell receptor-dependent lysis of malignant glioma cell lines by human ?? T cells: Modulation by temozolomide and A disintegrin and metalloproteases 10 and 17 inhibitors. Oncoimmunology. 2016;5:e1093276 pubmed |
Vasu S, He S, Cheney C, Gopalakrishnan B, Mani R, Lozanski G, et al. Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts. Blood. 2016;127:2879-89 pubmed publisher |
Parrish C, Scott G, Migneco G, Scott K, Steele L, Ilett E, et al. Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia. Leukemia. 2015;29:1799-810 pubmed publisher |
Wang R, Sun P. Natural killer cell-mediated shedding of ULBP2. PLoS ONE. 2014;9:e91133 pubmed publisher |
Jacobs S, Plessers J, Pinxteren J, Roobrouck V, Verfaillie C, Van Gool S. Mutual interaction between human multipotent adult progenitor cells and NK cells. Cell Transplant. 2014;23:1099-110 pubmed publisher |
